Back to marketplace
S3VVASCULARTECHNOLOGIESSHAR· ISIN INE0HGT01012· Mysuru, Karnataka, India · Est. 2011 Verified
S3V Vascular Technologies Limited logo

S3V Vascular Technologies Limited

Healthcare & Hospitals
₹540-0.92%

vs. prev. close ₹545

52W High

₹545

52W Low

₹540

Market cap

₹1,049 Cr

IPO stage

No DRHP filed

CIN

U33112KA2011PLC059915

Price History

52W High

₹545

52W Low

₹540

About S3V Vascular Technologies Limited

Get the latest S3V Vascular Technologies unlisted share price. Buy or sell S3V Vascular Technologies shares with ease, stay updated with UnlistedZone.

1. Introduction S3V Vascular Technologies Limited, founded in 2011 and headquartered in Mysore, Karnataka, focuses on development and manufacturing of advanced medical devices for cardiovascular and critical-care applications. S3V became the first company to get the manufacturing license for an expandable titanium-based Intervertebral Body FusionDevice/Expandable Spinal Cage. The First Successful Spinal Implant was successfully done in Pune as well. Currently, S3V is the only company in the world to have this expandable Cage. 2. Business Model S3V follows a fully integrated model that combines in-house R&D, proprietary technology development, and regulated manufacturing facilities. It caters to both Indian and global markets through direct hospital partnerships, clinician collaborations, and medical-device distributors, ensuring cost-effective, high-quality medical devices. 3. Product Portfolio S3V manufactures high-end interventional medical products such as: i) Drug-Eluting Stents (DES) and Bare-Metal Stents ii) PTCA and Neurovascular Catheters iii) Esophageal and Biliary Stents iv) India’s first indigenous Mechanical Thrombectomy Device (for treating brain strokes)Its innovations are designed to reduce India’s import reliance in the medical-device segment while improving affordability and clinical access. 4. Industry & Market Opportunity With cardiovascular and neurovascular diseases rising rapidly, India represents a massive demand base for minimally invasive medical devices. The neuro-intervention market alone is a $2-billion segment, currently dominated by imported products. S3V targets this gap through indigenous manufacturing, regulatory compliance (ISO-13485, CE approvals), and reduction of import costs, increasing access in India and emerging markets. 5. Promoter Background – Mr. Badari Narayan Mr. Badari Narayan, the promoter of S3V Vascular Technologies, is a seasoned medical-devices expert with over 30 years of industry experience. He holds an M.

Company Details

Industry

Healthcare & Hospitals

Founded

2011

Headquarters

Mysuru, Karnataka, India

Min Lot Size

1

Face Value

₹10.00

Total Shares

19434502

Regulatory Information

Corporate Identity Number (CIN)

U33112KA2011PLC059915

PAN Number

AAQCS2303F

ISIN

INE0HGT01012

Key Valuation Ratios

As of FY2025 Annual · updated 26 Sept 2026Derived

Valuation

Market Cap

₹1,049.46 Cr

P/E Ratio

17,491.05×

P/S Ratio

77.39×

P/B Ratio

7.45×

EV / EBITDA

390.62×

Returns & Per Share

ROE

0.04%

EPS

₹0.03

Book Value / Share

₹72.45

Solvency

Debt / Equity

0.13×

Interest Coverage

1.14×

Company Fundamentals

As of FY2025 Annual · updated 26 Sept 2026

Gross Profit

₹3.23 Cr

EBITDA

₹2.71 Cr

Revenue Growth

-9.18%

Profit Margin

0.44%

Performance Trends

4 annual periods · derived from filed statements

As of FY2025 Annual · updated 26 Sept 2026

Revenue

₹ Cr

Net Profit

₹ Cr · losses in red

Earnings Per Share

₹ per share

Return on Equity

ROE %

Return on Capital Employed

ROCE %

Debt-to-Equity

0.13×

EBITDA Margin

19.99%

Interest Coverage

1.14×

Financial Statements

As of FY2025 Annual · updated 26 Sept 2026
Disclosed reportedDerived calculated
Line itemFY2022FY2023FY2024FY2025
Total Income
Revenue from operationsDisclosed21₹ Crore14.93₹ Crore14.93₹ Crore13.56₹ Crore
Other incomeDisclosed9₹ Lakh8₹ Lakh23₹ Lakh2.41₹ Crore
Total IncomeDerived21.09₹ Crore15.01₹ Crore15.16₹ Crore15.97₹ Crore
Expenses
Cost of goods soldDisclosed6.6₹ Crore8.53₹ Crore4.7₹ Crore10.33₹ Crore
Purchases of stock-in-tradeDisclosed—0₹ Crore0₹ Crore0₹ Crore
Changes in inventoriesDisclosed1.1₹ Crore-57₹ Lakh78₹ Lakh-6.97₹ Crore
Employee benefits expenseDisclosed2₹ Crore2.57₹ Crore2.79₹ Crore4.75₹ Crore
Finance costsDisclosed1.4₹ Crore1.31₹ Crore3.56₹ Crore1.16₹ Crore
Depreciation and amortization expenseDisclosed1.5₹ Crore1.73₹ Crore2.07₹ Crore1.39₹ Crore
Manufacturing expensesDisclosed—0₹ Crore0₹ Crore0₹ Crore
Operating expensesDisclosed—0₹ Crore0₹ Crore0₹ Crore
Other expensesDisclosed5.5₹ Crore79₹ Lakh4.32₹ Crore5.97₹ Crore
Total ExpensesDerived18.1₹ Crore14.36₹ Crore18.22₹ Crore16.63₹ Crore
Profit
Exceptional itemsDisclosed—0₹ Crore0₹ Crore82₹ Lakh
Profit before taxDerived2.99₹ Crore65₹ Lakh-3.06₹ Crore16₹ Lakh
Current tax expenseDisclosed—9₹ Lakh14₹ Lakh10₹ Lakh
Deferred tax expenseDisclosed—0₹ Crore0₹ Crore0₹ Crore
Tax expenseDisclosed10₹ Lakh9₹ Lakh14₹ Lakh10₹ Lakh
Profit After TaxDerived2.89₹ Crore56₹ Lakh-3.2₹ Crore6₹ Lakh
Other comprehensive incomeDisclosed0₹ Crore0₹ Crore0₹ Crore0₹ Crore
Total Comprehensive IncomeDerived2.89₹ Crore56₹ Lakh-3.2₹ Crore6₹ Lakh

Documents Library

Access all financial reports and filings

Annual Report

Annual Report 2025

2025
0.3 MB

annual report 2024

2024
0.6 MB

Income Statement

financial result 2023

2023
0.6 MB

Document

S3V s Allotment of CCPS of 8.45 Cr corporate acti

0.5 MB

S3V s Allotment of CCPS of 89.92 Cr corporate act

0.6 MB

Shareholding Pattern

Others

56.23%

N G Badari Narayan

16.76%

Narayan Kalindhi

8.43%

L&T Welfare Company Ltd

7.41%

N G Vijaya Gopal

6.12%

N G Vishnu Shreyas

5.05%

B

Badari Narayan

MD & CEO

25+

LinkedIn
V

Vijaya Gopal Nagaradagadde

Director, Co-founder

15+

LinkedIn

S3V's Allotment of CCPS of ₹8.45 Cr corporate_action Allotment of 4,80,123 Non-Cumulative Compulsorily Convertible Preference Shares (CCPS) on a preferential basis.

corporate action
26/03/2024

S3V's Allotment of CCPS of ₹8.45 Cr corporate_action Allotment of 4,80,123 Non-Cumulative Compulsorily Convertible Preference Shares (CCPS) on a preferential basis.

S3V's Allotment of CCPS of ₹89.92 Cr corporate_action Allotment of 51,09,183 CCPS @176/share on a preferential basis.

corporate action
13/03/2024

S3V's Allotment of CCPS of ₹89.92 Cr corporate_action Allotment of 51,09,183 CCPS @176/share on a preferential basis.

Express buy interest

No commitment — the desk will reach out

Current Price

₹540
-0.92%
Min lot: 1
Price/share₹540
Quantity100
Estimated Total₹54,000

Secure & Verified Transaction

Unlisted shares are illiquid and carry higher market risks. Please read the Risk Disclosure before investing.

Talk to a Specialist

Get expert guidance on this investment

52 Week Range
₹540
₹545

About S3V Vascular Technologies Limited unlisted shares

Indicative · updated daily

S3V Vascular Technologies Limited unlisted share price today

S3V Vascular Technologies Limited unlisted share price today is ₹540 as of 16 October 2026.

S3V Vascular Technologies Limited — frequently asked questions

What is the grey market price for S3V Vascular Technologies Limited?

No IPO is currently announced for S3V Vascular Technologies Limited, so no grey market exists; the price above reflects Priveq's own desk valuation.

Has S3V Vascular Technologies Limited filed for an IPO, and when might it list?

S3V Vascular Technologies Limited has not filed a draft red herring prospectus, so no IPO is currently announced and no listing date has been set.

How does S3V Vascular Technologies Limited compare to its listed peers?

There is no closely comparable listed company for S3V Vascular Technologies Limited in India today.

Is S3V Vascular Technologies Limited on the SME or Mainboard IPO track?

S3V Vascular Technologies Limited has not filed a draft red herring prospectus, so no IPO track is set yet.

What is S3V Vascular Technologies Limited's CIN and registered office?

S3V Vascular Technologies Limited's Corporate Identity Number is U33112KA2011PLC059915, registered at Mysuru, Karnataka, India .

What is S3V Vascular Technologies Limited's market capitalisation?

S3V Vascular Technologies Limited's market capitalisation is approximately ₹1,049 crore, based on its current unlisted share price.

All Healthcare & Hospitals →

Buying, selling and holding unlisted shares

Applies to every company on Priveq
How do I buy S3V Vascular Technologies Limited unlisted shares?

Priveq Investech Private Limited is the named counterparty on every transaction. To buy S3V Vascular Technologies Limited unlisted shares: complete KYC once (PAN, Aadhaar, bank details, and demat account information — SEBI-compliant, typically approved within 24 hours), then submit your order through your Priveq dashboard specifying quantity. Our team confirms price and payment details with you directly. Once payment is confirmed, S3V Vascular Technologies Limited shares are transferred off-market straight to your demat account, with no pooling and no middlemen.

How do I sell S3V Vascular Technologies Limited unlisted shares?

Submit an Express Sell Interest for S3V Vascular Technologies Limited through your Priveq dashboard, specifying quantity, the same way a buy order is placed. Priveq quotes you a bid price, which may differ from the live Buy price shown to buyers, since unlisted-share pricing works on a bid-ask basis rather than a single quote. Once you accept, you'll need to provide your Client Master List (CML), a cancelled cheque or bank details, and PAN. If you hold shares with CDSL, transfer can also be completed digitally via CDSL Easiest. You transfer S3V Vascular Technologies Limited shares to Priveq first, and payment follows once the transfer is confirmed received, typically the same day, T+1, or occasionally T+2, communicated to you directly. For sizeable transactions worth crores of rupees, an escrow arrangement can be used instead, at the sole consent of both parties.

What is the minimum investment for S3V Vascular Technologies Limited unlisted shares?

Minimum investment varies by company and is shown as the Min Investment figure on this page. S3V Vascular Technologies Limited's minimum is ₹540.

Is there a maximum investment limit?

There's no fixed maximum investment limit for S3V Vascular Technologies Limited unlisted shares. For sizeable transactions worth crores of rupees, an escrow arrangement can be used at the sole consent of both parties, the same mechanism available on the sell side.

Is buying S3V Vascular Technologies Limited unlisted shares legal in India?

Yes. Buying and selling unlisted shares in India is legal and is subject to relevant SEBI regulations, including the mandatory lock-in period after listing, stamp duty, and depository participant charges on each transaction. Priveq's own KYC process is built to be SEBI-compliant.

What is the lock-in period for S3V Vascular Technologies Limited unlisted shares?

S3V Vascular Technologies Limited has not filed a DRHP yet, so no listing date or lock-in period applies at this stage. Once an IPO is filed, this answer updates to reflect the applicable SME or Mainboard lock-in.

What happens if S3V Vascular Technologies Limited's IPO is delayed or withdrawn?

If an IPO is delayed, shares remain unlisted and continue to trade on the desk at Priveq's indicative price, with no lock-in in effect until an actual listing happens. If a company formally withdraws its DRHP, the same applies: shares stay unlisted, with no lock-in period until and unless a fresh IPO process begins.

How are capital gains on S3V Vascular Technologies Limited unlisted shares taxed?

If you sell unlisted shares, including S3V Vascular Technologies Limited, within 24 months of purchase, the gain is taxed as short-term capital gain at your applicable income tax slab rate. Beyond 24 months, it is taxed as long-term capital gain at 12.5 percent, without indexation benefit, under the rules effective from 23 July 2024. If S3V Vascular Technologies Limited lists and you sell after listing, the applicable tax treatment shifts to listed-security rates, with the holding period still measured from your original unlisted purchase date. This is general information, not tax advice; investors should confirm their specific position with a tax advisor.

Can NRIs invest in S3V Vascular Technologies Limited unlisted shares?

Yes, on a non-repatriable basis. NRIs can invest using funds from an NRO account; sale proceeds stay within India unless repatriated separately under RBI's own limits. Priveq does not currently support repatriable investment (NRE/FCNR-funded), which would require the investee company to file additional RBI paperwork as foreign direct investment.

Does Priveq charge a platform fee on top of the share price?

No. The price quoted to you is all-in; there is no separate platform fee or brokerage added on top.

How does Priveq determine the desk price for S3V Vascular Technologies Limited?

Priveq's desk price reflects several inputs together, not a single formula: the seller's ask price at the time, current demand and supply on the platform for S3V Vascular Technologies Limited specifically, broader sentiment in the unlisted and pre-IPO market, how S3V Vascular Technologies Limited's sector and listed peers are trading, the company's own recent financial performance and IPO-stage developments, and recent transaction history where deals have actually closed.

Because unlisted shares trade over the counter rather than on an exchange, this price is indicative, not a continuously live quoted market price, and the actual deal price is confirmed with you directly before a transaction closes.

Is Priveq SEBI-registered? Does it give investment advice?

Priveq is not a SEBI-registered stock exchange and not a SEBI-registered investment adviser. Priveq Investech Private Limited operates Priveq.in as a research and information platform for unlisted and pre-IPO shares, and is the named counterparty on transactions executed through the platform. Nothing on this page is investment advice; it's information to help you evaluate a company and decide for yourself.

Am I eligible to invest through Priveq if I'm not an HNI?

Yes. Priveq isn't a stock exchange with membership restrictions, and investing isn't limited to HNIs. Depending on the company, entry points can start as low as ₹20,000, though the minimum for any specific company is shown as the Min Investment figure on its page.

What documents do I receive after buying unlisted shares?

You receive an email acknowledging and confirming your order, along with a deal note or invoice recording the transaction details.

What happens to my shares or money if a deal falls through?

Because Priveq is the direct counterparty on every transaction rather than just connecting a buyer and seller, this risk sits with Priveq, not with you. If a deal falls through after you've committed funds or shares, they remain safe, and Priveq guarantees a refund.

Chat with us